To demonstrate the efficacy of a ready-to-graft 3D neural microtissue product – manufactured at large scale - as a therapeutically viable option to treat Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Prudon et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: